SWOG clinical trial number
S1826

A Phase III, Randomized Study of Nivolumab (Opdivo) Plus AVD or Brentuximab Vedotin (Adcetris) Plus AVD in Patients (Age >/= 12 years) with Newly Diagnosed Advanced Stage Classical Hodgkin Lymphoma

Open
Phase
Accrual
1%
Abbreviated Title
Phase III Study of AVD plus nivolumab or BV in pts >/= 12 years in newly diagnosed, advanced cHL
Status Notes
Activation - Effective 7/19/19
Activated
07/19/2019
Participants
ALL NATIONAL CLINICAL TRIALS NETWORK MEMBERS LISTED ON TITLE PAGE

Research committees

Lymphoma

Treatment

Doxorubicin Filgrastim Vinblastine Sulfate Pegfilgrastim Nivolumab Brentuximab Vedotin Dacarbazine RT

Eligibility Criteria Expand/Collapse

See Section 5.0 of the S1826 protocol posted on www.ctsu.org

Reports & Approvals

Trial Locations